The JV intends is to produce Neovacs’ Kinoid immunotherapy product candidates, including IFNa-Kinoid. Under the deal, Stellar and Neovacs will establish a production firm, dubbed Neostell SAS, based
About 60,000 people in the US are diagnosed with DTC per year, and radioactive iodine (RAI) is recommended for those with known/suspected metastases at diagnosis and at high
GR-MD-02 targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. The trial, which has enrolled 30 patients with advanced fibrosis, will last for
The new macromolecule features various specialized components that create a triple-play action to avoid drug resistance. A specialized component of the macromolecule allows better hydrogen bonds with electrostatic
The commission granted approval for Bristol-Myers Squibb’s (BMS) Opdivo in combination with Yervoy to treat advanced (unresectable or metastatic) melanoma in adults. In the first Phase 3, double-blind,
The regulator confirmed that the proposed comparator is acceptable and the trial design would meet the requirements established in its guidance for ABSSSI studies. In addition, the FDA
New Leaf Venture Partners led the financing, which included new investors Frazier Healthcare Partners, Longitude Capital, and Osage University Partners. Existing investors Adams Street Partners, LVP Life Science
DRM01 is a novel, small molecule designed to inhibit sebum production after topical application to treat acne. It is designed to target acetyl coenzyme-A carboxylase, an enzyme that
Takeda will use the funding tob develop, license and supply about 50 million doses per year of Sabin-strain inactivated poliovirus vaccine (sIPV) to over 70 developing countries. The
Under the deal, Incyte will make a $140m upfront payment to Ariad plus pay royalties of up to 50% on European sales of Iclusig. Incyte will also take
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.